ClinicalTrials.gg
Status unknownNCT03388840Updated Sep 18, 2018

Adipose Derived Stem Cells Versus Platelet Rich Plasma on Follicular Unit Extraction

A Phase 4 interventional study of Adipose derived stem cells suspention and Platelet rich plasma in Androgenetic Alopecia, sponsored by Assiut University. Status unknown at 1 site in Egypt. Open to male participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2018-09-18.

Sponsored by Assiut University · Phase 4, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Feb 2018), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 25 studies in Alopecia with a site in Egypt — 9 open to participants now, 9 under way, 1 of them phase 3. Alopecia · Egypt.

Planned enrollment
10th of 21
40 · median 40
Started
2018
with 2 others
Phase 4
5 of 25
1 open now
Registered
3rd of 25
by date
Lead sponsor
4 of 25
Assiut University

Among the 25 studies in Alopecia with a site in Egypt, this one is the 10th largest by planned enrollment of the 21 interventional ones that give a count, is one of 3 that started in 2018, is one of 5 in phase 4, and was the 3rd registered.

Alopecia

512 studies on the registry are indexed under Alopecia; 129 are open to participants now.

Browse Alopecia studies →

Open to participants now

9 of the 25 studies in Alopecia with a site in Egypt are open now. Recruiting first, the newest first:

4 more — sign in →

All 9 open studies →

A study can be open while its sites in Egypt have not opened yet or have stopped. Only those recruiting at a site in Egypt →

Who these studies take

Of the 75 Alopecia studies recruiting now, 25 (33%) set no upper age limit and 46 (61%) stop at 75 or younger; 9 take children under 18; 24 take healthy volunteers.

This study: 18 Years to 60 Years · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 25 studies in Alopecia with a site in Egypt, or all of them as a file.
02

Study summary

Androgenetic alopecia is the most common type of alopecia in both men and women. About 80 % of Caucasian men and 40-50 % of Caucasian women are affected by androgenetic alopecia. The psychological impact of hair loss due to Androgenetic alopecia can be profound.

Read the detailed description

Currently, two medications are Food and Drug Administration approved in the treatment of Androgenetic alopecia which are minoxidil, and finasteride. Both medications must be taken indefinitely for benefits to persist. Hair transplantation is the only current successful permanent option. Nowadays, the majority of surgeons use 2 techniques, the classic strip technique, and the follicular unit extraction technique. Advantages of follicular unit extraction over the strip technique are the lesser incidence of donor zone post-procedural discomfort and the barely visible scarring.

Platelet rich plasma is an autologous concentration of platelets in small volume of plasma and is an exciting therapeutic option for hair growth. Combining platelet rich plasma with follicular unit extraction surgery for the treatment of Androgenetic alopecia demonstrated that PRP is able to minimize the postsurgical follicle loss and potentiate the performance of grafted hairs.

Adipose derived stem cells are an effective mesenchymal stem cell population with enormous potential in different fields of regenerative medicine.

Adipose stem cells are needed to induce the proliferation of bulge stem cells of hair follicle. Furthermore, they can help in wound healing and vascular neogenesis.

Zanzottera et al. 2014 investigated the effect of adipose derived stem cells on wound healing and engraftment of the transplanted hair applied during hair restoration surgery for three patients with androgenetic alopecia. Despite their promising results, further clinical trials including larger number of patients are still needed to confirm their preliminary findings.

03

Conditions studied

  • Androgenetic Alopecia

Browse trials for

Keywords

  • platelet rich plasma
  • adipose derived stem cells
  • follicular unit extraction
  • hair transplantation
04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • male patients with androgenetic alopecia between 18 years and 60 years

Exclusion criteria

Exclusion Criteria:

  1. Patients with Non-androgenetic causes of hair loss.
  2. Female patients with androgenetic alopecia.
  3. Patients who received anti-hair loss treatment within the past six months.
  4. Patients with history of bleeding disorders or on anticoagulant therapy.
  5. Patients with history of chronic liver disease, cancer or connective tissue disorders.
  6. Patients with current scalp infection.
05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    Adipose derived stem cells suspention

    suspension rich in adipose derived stem cells plus platelet rich plasma will be injected at the recipient site during follicular unit extraction for treatment of androgenetic alopecia

    Biological: Adipose derived stem cells suspention

  • Active comparator
    Platelet rich plasma

    platelet rich plasma will be injected at the recipient site during follicular unit extraction for treatment of androgenetic alopecia

    Biological: Platelet rich plasma

Interventions

  • BiologicalAdipose derived stem cells suspention

    application of adipose derived stem cells to the engrafted hair in hair transplantation surgery

  • application of autologous platelet rich plasma to the engrafted hair in hair transplantation surgery

06

What researchers measure

Primary outcomes

  1. hair growth

    Evaluate the effect of adipose derived stem cells intradermally injected in the recipient site during follicular unit extraction for the treatment of androgenetic alopecia on transplanted hair growth in terms of hair density (number of hairs / cm2) in the transplanted region using folliscope.

    Time frame: 12 months

Secondary outcomes

  1. hair shaft diameter

    Evaluate the effect of adipose derived stem cells intradermally injected in the recipient site during follicular unit extraction for the treatment of androgenetic alopecia on transplanted hair shaft diameter in mm using folliscope.

    Time frame: 12 months

07

Study locations

1 of 1 sites recruiting
  • Assiut university hospitals
    Assiut, Egypt
    Recruiting
08

References and documents

Publications

  • Adil A, Godwin M. The effectiveness of treatments for androgenetic alopecia: A systematic review and meta-analysis. J Am Acad Dermatol. 2017 Jul;77(1):136-141.e5. doi: 10.1016/j.jaad.2017.02.054. Epub 2017 Apr 7. PubMed 28396101 ↗
  • Navarro RM, Pino A, Martinez-Andres A, Molina C, Martinez AM, Martinez N, Orive G, Anitua E. The effect of plasma rich in growth factors combined with follicular unit extraction surgery for the treatment of hair loss: A pilot study. J Cosmet Dermatol. 2018 Oct;17(5):862-873. doi: 10.1111/jocd.12446. Epub 2017 Oct 26. PubMed 29076290 ↗
  • Jimenez-Acosta F, Ponce-Rodriguez I. Follicular Unit Extraction for Hair Transplantation: An Update. Actas Dermosifiliogr. 2017 Jul-Aug;108(6):532-537. doi: 10.1016/j.ad.2017.02.015. Epub 2017 May 5. English, Spanish. PubMed 28483047 ↗
  • Qi J, Garza LA. An overview of alopecias. Cold Spring Harb Perspect Med. 2014 Mar 1;4(3):a013615. doi: 10.1101/cshperspect.a013615. PubMed 24591533 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jan 2018 (actual). Primary completion is estimated for Jan 2021, 36 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 23, 2017
First posted
Jan 3, 2018
StartActual
Jan 15, 2018
Primary completionEst.
Jan 2021
CompletionEst.
Mar 2021
Last update
Sep 18, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 18, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03388840
Lead sponsor
Assiut University
Responsible party
A Ghazally (principal investigator, Assiut University) — Principal investigator
First posted
Jan 3, 2018
Start date
Jan 15, 2018
Primary completion
Jan 2021 (estimated)
Completion
Mar 2021 (estimated)
Last update
Sep 18, 2018

Study contacts

Azza M Abdel-Meguid, PHD
Contact
azzamahfouz@yahoo.com
01001801039
Doaa A Abou-Taleb, PHD
Contact
dodda_aboutaleb@yahoo.com
01001463937
Alaa H Ghazally, MD
principal investigator · Assiut University

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Feb 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion